Tarsus Pharmaceuticals, Inc.
TARS
You’ve read what changed. Here’s whether the market is confirming it.
Jodie situation report
Tarsus Pharmaceuticals, Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 10 of 12 group members are active now; 2 filing-linked outsiders are moving with the group, and 1 of 10 directly disclosed connections are confirming.
- Participation remains broad in the next market snapshot.
- PFE remains aligned with the group in the next market snapshot.
Invalidation: This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Who this business touches
The relationships behind TARS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LIANYFiling-linked namepartnerFeb 23, 2026 ▾
“In March 2021, we entered into the China Out-License with LianBio Ophthalmology Limited (“LianBio”), granting exclusive commercial rights of TP-03 for the treatment of Demodex blepharitis and MGD within the China Territory.”
MRNAModerna, Inc.partnerFeb 23, 2026 ▾
“We are aware of vaccines currently under development including a multivalent recombinant protein vaccine, VLA-15, being developed by Valneva in partnership with Pfizer for Lyme disease; mRNA-based vaccine mRNA-1982/1975, being developed by Moderna and eliciti…”
Depended on by
HTGCHercules Capital, Inc.investeeOct 30, 2025 ▾
“The net realized gains (losses) were generated from gross realized gains of $2.8 million and $17.8 million respectively, for the three and nine month periods, primarily from the sale of our equity and warrant positions in Palantir Technologies, TransMedics Gr…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TARS is currently a Early Follower in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.